We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase 2 Trial of Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus Methotrexate- Cytarabine for Relapsed or Refractory Aggressive Mantle Cell Lymphoma.
- Authors
Wang, Michael; Fayad, Luis; Cabanillas, Fernando; Hagemeister, Fredrick; McLaughlin, Peter; Rodriguez, Maria A.; Kwak, Larry W.; Yuhong Zhou; Kantarjian, Hagop; Romaguera, Jorge
- Abstract
The article presents the clinical trial of several antineoplastic agents including rituximab, methotrexate, and cytarabine which treat patients with refractory mantle cell lymphoma (MCL) in the U.S. It notes that toxicity, neutropenic fever, and thrombocytopenia are the side effects of the anticancer agents. Moreover, it emphasizes the effectiveness of chemotherapeutic agents including cyclophosphamide, vincristine, and doxorubicin on treating MCL.
- Subjects
UNITED States; ANTINEOPLASTIC agents; LYMPHOMA treatment; DRUG side effects; IMMUNOSUPPRESSIVE agents
- Publication
Cancer (0008543X), 2008, Vol 113, Issue 10, p2734
- ISSN
0008-543X
- Publication type
Article
- DOI
10.1002/cncr.23880